Bluejay Diagnostics, Inc.
No SEC Form 4 filings for $BJDX in the last 30 days.
See all $BJDX insider activity →Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare
Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
Bluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BJDX (Bluejay Diagnostics, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BJDX coverage spans corporate actions, market movers and technology.
The agreement could unlock a large federal healthcare market, potentially boosting future revenues if FDA clearance is obtained.
Potential revenue boost from exclusive federal distribution.
Stronger liquidity and progress toward an FDA 510(k) are near-term positives, but commercialization timing remains uncertain.
The update reduces clinical execution risk and pairs it with a cash runway extension, supporting a near-term path to 510(k) readiness.
Enrollment completion de-risks trial execution and supports the timeline toward clinical reporting and an FDA 510(k) submission for the Symphony IL-6 test.
AlphAI scores every news story that mentions BJDX with an AI model for sentiment and relevance, and aggregates insider trades from Bluejay Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare
2 min readBluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.
3 min readBluejay Diagnostics (BJDX) reported Q2 2026 results with cash and cash equivalents rising to $9.6M from $5.2M at Dec. 31, 2025, an 84% increase, driven by $7.7M net cash from financing including $7.6M from a June private placement. The company completed pivotal enrolment of 750 patients in SYMON-II to support a planned FDA 510(k) for its Symphony IL-6 test.
5 min readBluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and said its SYMON-II pivotal study completed enrollment of 750 patients. The company is progressing toward analytical and clinical validation for a planned FDA 510(k) submission and signed a US manufacturing contract. Cash rose to about $9.6M at June 30, 2026 from $5.2M at Dec. 31, 2025, after a June private placement.
6 min readBluejay Diagnostics (BJDX) said it completed patient enrollment in its pivotal SYMON-II sepsis study, reaching 750 patients ahead of schedule. The multicenter validation evaluates its Symphony IL-6 test for predicting 28-day mortality risk in ICU sepsis patients. The company plans data analysis and expects results to support an FDA 510(k) submission.
2 min readHRT FINANCIAL LP purchased 64,047 shares of Bluejay Diagnostics, Inc. (BJDX) at $1.51 on 2026-07-09.
2 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029420901ex10-1.htm BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO. 1 THERETO Exhibit 10.1 BLUEJAY DIAGNOSTICS, INC. 2021 STOCK PLAN, AS AMENDED BY AMENDMENT NO.1 THERETO Section 1. Establishment and Purpose. 1.1 The Board of Directors (the “Boa
3 min readBluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029339001ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 2, 2026, between Bluejay Diagnostics, Inc., a Delaware corporation (the “ Company ”), and e
6 min readBluejay Diagnostics (NASDAQ: BJDX) said it closed a private placement under Nasdaq rules, selling 3,655,917 shares (or pre-funded warrants) plus Series G and short-term Series H warrants at $2.325 per share. Gross proceeds were $8.5 million, with up to ~$15.2 million more if warrants are fully exercised for cash. The company expects net proceeds to fund operations into Q1 2027.
5 min readHealthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin
6 min read
